AWP Reform Reporting Requirements Need Clear Definition, PhRMA Says

The Centers for Medicare & Medicaid Services should clearly define reporting requirements for manufacturers associated with payment reform for Part B drugs, the Pharmaceutical Research & Manufacturers of America said